Psychiatr. pro Praxi, 2006; 5: 235-240

EFEKTIVITA LÉČBY SCHIZOFRENIE VE SVĚTLE DVOU FÁZÍ STUDIE CATIE

MUDr. Jiří Masopust
Psychiatrická klinika LF UK a FN Hradec Králové

Práce nabízí komentovaný přehled prvních dvou fází nezávislé studie Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Cílem sledování bylo posouzení efektivity léčby antipsychotiky. Hlavním měřítkem byla doba do přerušení léčby z jakékoliv příčiny. Porovnávána byla nejčastěji užívaná antipsychotika II. generace navzájem a dále se zástupcem klasických neuroleptik perfenazinem. Nemocní neúspěšně léčení v první fázi studie mohli být ve druhé fázi randomizováni k léčbě klozapinem nebo antipsychotikem II. generace jiným, než které dosud užívali. Studie potvrdila, že mezi antipsychotiky jsou rozdíly z hlediska efektivity a nežádoucích účinků. Autor se ve sdělení zabývá nejčastějšími námitkami k uspořádání a výsledkům studie a podává k nim komentáře.

Published: December 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Masopust J. EFEKTIVITA LÉČBY SCHIZOFRENIE VE SVĚTLE DVOU FÁZÍ STUDIE CATIE. Psychiatr. praxi. 2006;7(5):235-240.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Anders M. Kritika závěrů studie CATIE aneb jak složité je zkoumat léčbu antipsychotiky. Psychiat. pro praxi 2006; 7: 50-52.
    2. Basil B, Mathews M, Adetunji B, Budur K. The CATIE Study (letter). Am J Psychiatry 2006; 163: 555.
    3. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psych 2003; 60: 553-564. Go to original source... Go to PubMed...
    4. Davis JM. The choice of drugs for schizophrenia. N Engl J Med 2006; 354: 518-520. Go to original source... Go to PubMed...
    5. Fleishacker WW, Keet IP, Kahn RS. The european first episode schizophrenia trial (EUFEST): rationale and design of the trial. Schizophr Res 2005; 78: 147-156. Go to original source... Go to PubMed...
    6. Haddad PM, Dursun S. Selecting antipsychotics in schizophrenia: lessons from CATIE. J Psychopharmacol 2006; 20: 332-334. Go to original source... Go to PubMed...
    7. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006; 163: 185-194. Go to original source... Go to PubMed...
    8. Kane JM. Commentary on the clinical antipsychotic trials of intervention effectiveness (CATIE). J Clin Psychiatry 2006; 67: 831-832. Go to original source... Go to PubMed...
    9. Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, Meltzer HY, Green MF, Miller DD, Canive JM, Adler LW, Manschreck TC, Swartz M, Rosenheck R, Perkins DO, Walker TM, Stroup TS, McEvoy JP, Lieberman JA. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006; 31 (v tisku). Go to original source... Go to PubMed...
    10. Lehman AF, Lieberman JA, Dixon LB et al. American Psychiatric Association. Am J Psychiatry 2004; 161(Suppl 2): 1-56.
    11. Leucht S, Barnes TRE, Kissling W, Engel RR, Correll CH, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory metaanalysis of randomized, controlled trials. Am J Psychiatry 2003a; 160: 1209-1222. Go to original source... Go to PubMed...
    12. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003b; 361: 1581-1589. Go to original source... Go to PubMed...
    13. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patiens with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223. Go to original source... Go to PubMed...
    14. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Hsiao J, Severe J, Lebowitz BD. Dr. Lieberman and colleagues reply. Am J Psychiatry 2006; 163: 555-556. Go to original source...
    15. Lieberman JA, Stroup TS, Davis SM. (letter). N Engl J Med 2006; 354: 300. Go to original source...
    16. Libiger J. Treatment in the early stages of psychosis. In: Miller T, Mednick SA, McGlashan TH, Libiger J, Johannessen JO. Early intervention in psychotic disorders. Dordrecht: Kluwer Academic Publishers 2001; 181-195. Go to original source...
    17. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RSE, Davis CE, Severe J, Hsiao JK. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163: 600-610. Go to original source...
    18. Miller D, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chaos MH, Swartz MS, Keefe RS, Rosenheck RA, Stroup TS, Lieberman JA. Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial. Schizophr Res 2005; 80: 33-43. Go to original source... Go to PubMed...
    19. Mohr P, Czobor P. Subject selection for the placebo- and comparator-controlled trials of neuroleptics in schizophrenia. J Clin Psychopharmacol 2000; 20: 240-245. Go to original source... Go to PubMed...
    20. Möller HJ. Are the new antipsychotics no better than the classical neuroleptics? The problematic answer from the CATIE study. Eur Arch Psychiatry Clin Neurosci 2005; 255: 371-372. Go to original source... Go to PubMed...
    21. Stahl SM. Essential psychopharmacology. The prescriber's guide. Cambridge: Cambridge University Press 2005; 571.
    22. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA. The National institute of mental health clinical antipsychotic trials of intervention effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003; 29: 15-31. Go to original source... Go to PubMed...
    23. Stroup TS, Lieberman, JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RSE, Davis CE, Severe J, Hsiao JK. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006; 163: 611-622. Go to original source...
    24. Švestka J. Antipsychotika. In: Höschl C, Libiger J, Švestka J. Psychiatrie. 2. vydání. Praha: Tigis 2004; 696-708.
    25. Teich J. The CATIE Study (letter). Am J Psychiatry 2006; 163: 554-555.
    26. Tiihonen J, Wahlbeck K, Lönnquist J, Klaukka T, Ioannidis JPA, Volavka J, Haukka J. Effectiveness of antipsychotic treatments in a nation-wide cohort of 2230 patients in community care after the first hospitalization due to schizophrenia and schizoaffective disorder: observational follow-up study. Br Med J 2006; 333 (v tisku, dostupné na http://bmj.bmjjournals.com/cgi/rapidpdf/bmj.38881.382755.2Fv1). Go to original source... Go to PubMed...
    27. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002; 159: 255-262. Go to original source... Go to PubMed...
    28. Williams R, Kopala L, Malla A, Smith G, Love L, Balshaw R. Medication decisions and clinical outcomes in the Canadian national outcomes measurement study in schizophrenia. Acta Psychiatr Scand 2006; 113 (Suppl 430): 12-21. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.